A Double-blind, Placebo-controlled, Randomized INTerventional Clinical Trial (SARA-INT) (SARA-INT)
Safety and Efficacy of BIO-101 175 mg b.i.d. and 350 mg b.i.d. 26-week Oral Administration to Patients Suffering From Age-related SARcopenia, Including Sarcopenic Obesity, Aged ≥65 Years and at Risk of Mobility Disability
Sponsor: Biophytis
A PHASE2 clinical study on Gait Disorders in Old Age and Muscle Weakness, this trial is completed. The trial is conducted by Biophytis and has accumulated 16 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
16 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Oct 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Sep 2021 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
▶ Show 11 earlier versions
-
Jan 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Aug 2020 — Dec 2020 [monthly]
Recruiting PHASE2
-
Mar 2020 — Aug 2020 [monthly]
Recruiting PHASE2
-
Nov 2019 — Mar 2020 [monthly]
Recruiting PHASE2
-
Jul 2019 — Nov 2019 [monthly]
Recruiting PHASE2
-
Jun 2019 — Jul 2019 [monthly]
Recruiting PHASE2
-
Dec 2018 — Jun 2019 [monthly]
Recruiting PHASE2
-
Jul 2018 — Dec 2018 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2018 — Jul 2018 [monthly]
Not Yet Recruiting PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Not Yet Recruiting PHASE2
First recorded
Feb 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Biophytis
For direct contact, visit the study record on ClinicalTrials.gov .